Adalimumab Biosimilar - Mycenax Biotech

Drug Profile

Adalimumab Biosimilar - Mycenax Biotech

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mycenax Biotech
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 09 Aug 2017 Adalimumab Biosimilar - Mycenax Biotech is available for licensing as of 09 Aug 2017.
  • 09 Aug 2017 Early research in Ankylosing spondylitis in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)
  • 09 Aug 2017 Early research in Crohn's disease in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top